Commodities tumble while pharma stocks rise

Both base and precious metals have sold off today as the pessimism over struggling demand intensifies.

London
Source: Bloomberg

The appeal of mining companies has become increasingly difficult to see, as increasing production levels coupled with dwindling demand has given little reason to believe a bounce in the sector will soon materialise.

The performance of oil today would suggest that regardless of how uncomfortable OPEC members might be with the current oversupply to the markets, change is not anticipated.

Saudi Arabia looks unwilling to change from this current template and today’s oil inventories oversupply has just given fresh impetus to the bears ahead of OPEC’s Vienna meeting. The writing has been on the  wall for some time and overnight the decision will be made on Meggitt, G4S and Morrison’s eligibility to stay in the FTSE 100.

The pharmaceutical sector has done its best to drag the FTSE higher with Shire, GlaxoSmithKline and AstraZeneca making up the bulk of the best performing equities.

As successful as European Central Bank president Mario Draghi may have been in talking down the euro, his sheer will power alone has failed to prevent the eurozone inflation picture from becoming even worse.

The ADP employment date has never been the most reliable indicator ahead of Friday’s non-farm payrolls but the better-than-expected figures, along with the improved revision from the previous month, has given fresh power to GBP/USD as today’s moves have seen it smash through the psychological $1.500 barrier with consummate ease.

With Federal Reserve chair Janet Yellen yet to talk and the latest Fed Beige book due for release tonight, the selloff could still see lower lows.

Denne informasjonen er utarbeidet av IG, forretningsnavnet til IG Markets Limited. I tillegg til disclaimeren nedenfor, inneholder ikke denne siden oversikt over kurser, eller tilbud om, eller oppfordring til, en transaksjon i noe finansielt instrument. IG påtar seg intet ansvar for handlinger basert på disse kommentarene og for eventuelle konsekvenser som et resultat av dette. Ingen garanti gis for nøyaktigheten eller fullstendigheten av denne informasjonen. Personer som handler ut i fra denne informasjonen gjør det på egen risiko. Forskning gitt her tar ikke hensyn til spesifikke investeringsmål, finansiell situasjon og behov som angår den enkelte person som mottar dette. Denne informasjonen er ikke utarbeidet i samsvar med regelverket for investeringsanalyser, så derfor er denne informasjonen ansett å være markedsføringsmateriale. Selv om vi ikke er hindret i å handle i forkant av våre anbefalinger, ønsker vi ikke å dra nytte av dem før de blir levert til våre kunder. Se fullstendig disclaimer og kvartalsvis oppsummering.